Medical Weight Loss in India: What It Actually Involves

Quick answer: Medical weight loss means obesity treated as a medical condition — assessment, investigation, a treatment plan that may or may not include medication, and ongoing monitoring. A programme that prescribes a GLP-1 after a two-minute form is not medical weight loss; it is a sales funnel with a prescription attached.

Why obesity is treated medically now

The framing has shifted, and for good reason. Obesity involves hormonal appetite regulation, insulin dynamics, sleep, stress physiology and genetics — not simply choices. Treating it as a willpower problem produced decades of poor outcomes.

In India the case is particularly strong. The ICMR-INDIAB study estimated 101 million people with diabetes, 136 million with prediabetes and 254 million with generalised obesity — and Indians develop metabolic complications at lower BMIs than European populations.

What a real programme includes

• A proper assessment. BMI and waist circumference, medical and family history, current medications, sleep, and eating patterns.
• Blood work before treatment. Fasting glucose and HbA1c, thyroid function, lipids, liver markers. Untreated hypothyroidism, for example, needs treating in its own right — the American Thyroid Association notes weight change after levothyroxine is generally modest, so it is not a weight loss treatment, but it must be addressed.
• A plan that is not automatically a prescription. Lifestyle intervention has strong evidence: the Diabetes Prevention Program achieved a 58% reduction in progression to type 2 diabetes without weight loss drugs.
• Nutrition and activity support that fits how you actually eat, rather than a generic chart.
• Monitoring and follow-up, including muscle preservation — reviews of GLP-1 therapy identify protein intake and resistance training as necessary mitigations for lean-mass loss.
• A maintenance plan from the start, given the well-documented regain after stopping medication.

Where medication fits

Where clinically appropriate, and not otherwise. The evidence is genuinely strong — semaglutide produced a mean 14.9% body-weight reduction over 68 weeks in STEP 1, tirzepatide up to 20.9% over 72 weeks in SURMOUNT-1, and semaglutide reduced major adverse cardiovascular events by 20% in SELECT.

But these are prescription medicines with real side effects, real contraindications and an increased risk of gallbladder disease. In India they are Schedule H drugs, dispensed only against a valid prescription from a registered medical practitioner.

Warning signs of a bad programme

• A prescription without blood work or a proper consultation
• Guaranteed weight loss figures
• Pressure to buy long medication packages upfront
• No named, credentialed doctor you can identify
• Compounded or unapproved formulations
• No plan for what happens when you stop
• Markup on your medication rather than transparent at-cost pricing

Questions worth asking any provider

Who is the prescribing doctor and what are their credentials? What tests will you run before treating me? What happens if I do not tolerate the medication? What is the plan for maintenance? What exactly am I paying for, and is medication billed separately?

A good programme answers all of these readily. Hesitation on any of them is informative.